Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Dr. Stephen P.

United Kingdom

Staff Scientist at The Institute of Cancer Research

Profile Summary

My background is in experimental genetics with a focus on genetic screens and mutagenesis methods. Currently I am using CRISPR mutagenesis screens to investigate drug resistance mechanisms in breast cancer, particularly PARP inhibitors and other drugs targeting the DNA damage response. I attend and present at major international conferences in the genome engineering and targeted cancer therapy fields, giving me an in-depth knowledge of current research. I have expertise in the design and analysis of DNA sequencing experiments on Illumina, Ion Torrent and Oxford Nanopore platforms. I am experienced with many common alignment and analysis tools and scripting in R, Ruby and Perl. I also have an interest in software development for the web, using Ruby on Rails, Angular and React. Open source contributions can be viewed at github.com/stveep

Subject Matter Expertise

• ☆ Molecular Biology
• ☆ Genetics
• ☆ DNA Sequencing
• ☆ Bioinformatics
• ☆ Gene Editing/CRISPR
• ☆ Cancer Research

Services

• Writing
• Consulting
• Data & AI
• Product Development

Work Experience

Postdoctoral Fellow

Institute of Cancer Research

June 2011 - Present

JSPS Short Term Postdoctoral Fellow

RIKEN Center for Developmental Biology

January 2011 - May 2011

Education

PhD Genetics

Wellcome Trust Sanger Institute

September 2006 - December 2010

BA Natural Sciences

UNIVERSITY OF CAMBRIDGE

October 2003 - October 2006

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Pettitt, S.J., Lord, C.J.(2019). Dissecting PARP inhibitor resistance with functional genomics . Current Opinion in Genetics and Development. 54. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 55-63.

Chabanon, R.M., Muirhead, G., Krastev, D.B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al.(2019). PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer . Journal of Clinical Investigation. 129. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1211-1228.

Holme, H., Gulati, A., Brough, R., Fleuren, E.D.G., Bajrami, I., Campbell, J., Chong, I.Y., Costa-Cabral, S., Elliott, R., Fenton, T., et al.(2018). Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness . Scientific Reports. 8. (1).

Bajrami, I., Marlow, R., van De Ven, M., Brough, R., Pemberton, H.N., Frankum, J., Song, F., Rafiq, R., Konde, A., Krastev, D.B., et al.(2018). E-Cadherin/ROS1 inhibitor synthetic lethality in breast cancer . Cancer Discovery. 8. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 498-515.

Chong, I.Y., Aronson, L., Bryant, H., Gulati, A., Campbell, J., Elliott, R., Pettitt, S., Wilkerson, P., Lambros, M.B., Reis-Filho, J.S., et al.(2018). Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer . Gut. 67. (10). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1780-1792.

Pettitt, S.J., Lord, C.J.(2018). Parp inhibitors and breast cancer: Highlights and hang-ups . Expert Review of Precision Medicine and Drug Development. 3. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 83-94.

Barazas, M., Annunziato, S., Pettitt, S.J., de Krijger, I., Ghezraoui, H., Roobol, S.J., Lutz, C., Frankum, J., Song, F.F., Brough, R., et al.(2018). The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells . Cell Reports. 23. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2107-2118.

Noordermeer, S.M., Adam, S., Setiaputra, D., Barazas, M., Pettitt, S.J., Ling, A.K., Olivieri, M., Álvarez-Quilón, A., Moatti, N., Zimmermann, M., et al.(2018). The shieldin complex mediates 53BP1-dependent DNA repair . Nature. 560. (7716). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 117-121.

Holme, H., Gulati, A., Brough, R., Fleuren, E.D.G., Bajrami, I., Campbell, J., Chong, I.Y., Costa-Cabral, S., Elliott, R., Fenton, T., et al.(2018). Erratum to: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (Scientific Reports, (2018), 8, 1, (10614), 10.1038/s41598-018-29043-z) . Scientific Reports. 8. (1).

Pettitt, S.J., Krastev, D.B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M.I., Menon, M., Brough, R., Campbell, J., et al.(2018). Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance . Nature Communications. 9. (1).

Brough, R., Gulati, A., Haider, S., Kumar, R., Campbell, J., Knudsen, E., Pettitt, S.J., Ryan, C.J., Lord, C.J.(2018). Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer . Oncogene. 37. (43). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 5701-5718.

Krastev, D.B., Pettitt, S.J., Campbell, J., Song, F., Tanos, B.E., Stoynov, S.S., Ashworth, A., Lord, C.J.(2018). Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets . Nature Communications. 9. (1).

Dréan, A., Williamson, C.T., Brough, R., Brandsma, I., Menon, M., Konde, A., Garcia-Murillas, I., Pemberton, H.N., Frankum, J., Rafiq, R., et al.(2017). Modeling therapy resistance in BRCA1/2-mutant cancers . Molecular Cancer Therapeutics. 16. (9). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 2022-2034.

Jones, S.E., Fleuren, E.D.G., Frankum, J., Konde, A., Williamson, C.T., Krastev, D.B., Pemberton, H.N., Campbell, J., Gulati, A., Elliott, R., et al.(2017). ATR Is a therapeutic target in synovial sarcoma . Cancer Research. 77. (24). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 7014-7026.

Nikkilä, J., Kumar, R., Campbell, J., Brandsma, I., Pemberton, H.N., Wallberg, F., Nagy, K., Scheer, I., Vertessy, B.G., Serebrenik, A.A., et al.(2017). Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells . British Journal of Cancer. 117. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 113-123.

Pettitt, S.J., Krastev, D.B., Pemberton, H.N., Fontebasso, Y., Frankum, J., Rehman, F.L., Brough, R., Song, F., Bajrami, I., Rafiq, R., et al.(2017). Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells . Scientific Data. 4.

Pettitt SJ, Tan EP, Yusa K, Methods in molecular biology (Clifton, N.J.), 2015, vol. 1239, pp. 15-28, 2015 .

Li MA, Pettitt SJ, Eckert S, Ning Z, Rice S, Cadiñanos J, Yusa K, Conte N, Bradley A, Molecular and cellular biology, 2013, vol. 33, no. 7, pp. 1317-1330, 2013 .

Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A, PloS one, 2013, vol. 8, no. 4, pp. e61520, 2013 .

Pettitt, S.J., Rehman, F.L., Bajrami, I., Brough, R., Wallberg, F., Kozarewa, I., Fenwick, K., Assiotis, I., Chen, L., Campbell, J., et al.(2013). A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity . PLoS ONE. 8. (4).

Li, M.A., Pettitt, S.J., Eckert, S., Ning, Z., Rice, S., Cadiñanos, J., Yusa, K., Conte, N., Bradley, A.(2013). The piggybac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites . Molecular and Cellular Biology. 33. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 1317-1330.

Huang Y, Pettitt SJ, Guo G, Liu G, Li MA, Yang F, Bradley A, Nucleic acids research, 2012, vol. 40, no. 3, pp. e21, 2012 .

Huang, Y., Pettitt, S.J., Guo, G., Liu, G., Li, M.A., Yang, F., Bradley, A.(2012). Isolation of homozygous mutant mouse embryonic stem cells using a dual selection system . Nucleic Acids Research. 40. (3).

Li MA, Pettitt SJ, Yusa K, Bradley A, Methods in enzymology, 2010, vol. 477, pp. 217-242, 2010 .

Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR, Lloyd KC, Bradley A, Skarnes WC, Nature methods, 2009, vol. 6, no. 7, pp. 493-495, 2009 .

Pettitt, S.J., Liang, Q., Rairdan, X.Y., Moran, J.L., Prosser, H.M., Beier, D.R., Lloyd, K.C., Bradley, A., Skarnes, W.C.(2009). Agouti C57BL/6N embryonic stem cells for mouse genetic resources . Nature Methods. 6. (7). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 493-495.

BOOK

Pettitt, S.J., Tan, E.-P., Yusa, K.(2015). Piggybac transposon-based inser tional mutagenesis in mouse haploid embryonic stem cells . Methods in Molecular Biology. 1239. Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 15-28.

BOOK CHAPTER

Li, M.A., Pettitt, S.J., Yusa, K., Bradley, A.(2010). Genome-wide forward genetic screens in mouse ES cells . Methods in Enzymology. 477. (C). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 217-242.

OTHER

Pettitt SJ, 2011 .